ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,728.80
0.41%
US Tech 100
19,528.00
0.90%
Dow Jones
42,052.19
0.69%
Brent Oil
74.465
0.53%
Bitcoin
68,982.53
0.35%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Celyad Oncology SA (CYAD) Quote

Celyad Oncology SA

Celyad Oncology SA (CYAD)

Celyad Oncology SA
0.47
0.00
(0.00%)
Closed November 04 4:00PM
Delayed by 15 minutes
0.00
0.00
(0.00%)
After Hours: -
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
0.47
Bid
0.47
Ask
0.52
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Market Cap
19.472M
Previous Close
0.47
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
-
Shares Outstanding
41,429,000
Dividend Yield
-
PE Ratio
-1.42
Earnings Per Share (EPS)
-0.2
Revenue
102k
Net Profit
-8.45M

About Celyad Oncology SA

Celyad Oncology is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno Oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T and C-Cure. The firm h... Celyad Oncology is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno Oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T and C-Cure. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CATH and C-CATHez and CARDIO 3 BIOSCIENCES. The firm has Cardiology and Immuno-oncology operating segments. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.celyad.com
Headquarters
Mont-saint-guibert, Walloon Brabant, Bel
Founded
-

Ask ADVFN Intelligence (AI)

CYAD Latest News

More News

Celyad Oncology annonce la nomination de Matt Kane au poste de CEO

Regulatory News: Celyad Oncology SA (Euronext & Nasdaq : CYAD) (la « Société » ou « Celyad ») est heureuse d’annoncer la nomination de Matt Kane au poste de Directeur Général (Chief...

September 16 2024
Business Wire

Celyad Oncology Reports First Half Year 2024 Financial Results and Recent Business Highlights

The Company continues to bolster its intellectual property estate and to pursue options to monetize it The Company’s two main research and development platforms have delivered proof-of-concept...

September 13 2024
Business Wire

Celyad Oncology Reports Full Year 2023 Financial Results and Recent Business Highlights

Regulatory News: Celyad Oncology (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (the “Company”), today announces its financial results for the fiscal year 2023 ended December 31, 2023, and provides a...

April 04 2024
Business Wire

Celyad Oncology annonce son intention de mettre fin à ses obligations de déclaration à la SEC

Regulatory News: Celyad Oncology SA (Euronext: CYAD) (« Celyad Oncology » ou la «Société») annonce que la Société déposera volontairement un Formulaire 15F auprès de la Securities and Exchange...

February 08 2024
Business Wire

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

January 17 2024
Edgar (US Regulatory)

Celyad Oncology fait le point sur les activités du quatrième trimestre 2023 et présente ses perspectives pour 2024

Trois piliers principaux pour libérer le potentiel des plateformes technologiques propriétaires et de la propriété intellectuelle : Une plateforme technologique exclusive sans édition de génome...

January 16 2024
Business Wire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
VSTEVast Renewable Ltd
$ 4.98
(149.00%)
68.54M
INVZWInnoviz Technologies Ltd
$ 0.096
(96.71%)
22.71k
CDXCChromaDex Corporation
$ 5.87
(68.19%)
37.88M
ATHAAthira Pharma Inc
$ 0.606
(41.56%)
239.63M
TILEInterface Inc
$ 23.24
(33.03%)
2.16M
EPIXESSA Pharma Inc
$ 1.45
(-72.12%)
34.3M
ELABElevai Labs Inc
$ 0.0288
(-51.19%)
202.28M
OSTOstin Technology Group Company Ltd
$ 0.275
(-45.00%)
2.27M
LXRXLexicon Pharmaceuticals Inc
$ 1.23
(-36.92%)
21M
VCIGVCI Global Ltd
$ 0.0583
(-27.58%)
26.57M
ATHAAthira Pharma Inc
$ 0.606
(41.56%)
239.63M
SQQQProShares UltraPro Short QQQ
$ 7.44
(-2.11%)
216.16M
NVDANVIDIA Corporation
$ 135.40
(1.99%)
209.27M
ELABElevai Labs Inc
$ 0.0288
(-51.19%)
202.28M
INTCIntel Corporation
$ 23.20
(7.81%)
173.47M

Discussion

View Full Feed
Tally1! Tally1! 3 minutes ago
I see more promises like we’ve had last 15 years
Supposed to start trading Aug then mid Sept then mid Oct now in November and still nothing
Name change has occurred apparently awaiting on finra to activate but finra know nothing of what is apparently going on
CDBT
Tally1! Tally1! 4 minutes ago
I see more promises like we’ve had last 15 years
Supposed to start trading Aug then mid Sept then mid Oct now in November and still nothing
Name change has occurred apparently awaiting on finra to activate but finra know nothing of what is apparently going on
CDBT
TommyJ7651 TommyJ7651 5 minutes ago
Yup, Agnico is definitely one of the best miners out there right now. They have some land packages quite near Duparquet so it would definitely not be to far fetched for them to make a deal with us. Many investors are so focused on Springpole right now it seems they have completely forgotten about Du
AEM
gp22 gp22 8 minutes ago
$POET: Nuke play...AI chips for $AMZN, $MSFT & $ORCL Hyper Data Centers. $NNE, $OKLO & $LTBR investors finding too. Link:
https://poet-technologies.com/news/2024-oct-16.html
AMZN LTBR MSFT
linuxmanneke linuxmanneke 12 minutes ago
Some words used by Lebby have reached there expiration dates. If our shareprice was already (again) above 10 at least, you Will never heard me complainig about anything, and I will temper my impatience again... But here we are, at 3.xx after all those years. I spend a lot of money in this Company, a
LWLG
janice shell janice shell 17 minutes ago
And very good at this. He convinced quite a few of them to vote for Harris. I think 12...
fuagf fuagf 19 minutes ago
Pete is very patient.
janice shell janice shell 21 minutes ago
lolol.... Not totally convinced that grubs offer food for thought, but...
fuagf fuagf 23 minutes ago
Congratulations all. Lots of food for thought.
fuagf fuagf 26 minutes ago
Sad you think like that.
fuagf fuagf 28 minutes ago
Up 60 now. It's a lot.
fuagf fuagf 29 minutes ago
No. Two mistakes in one. lol
linuxmanneke linuxmanneke 37 minutes ago
Jeunke, I respect you very much, but my expectations are a little bit higher... It's almost (for me) seven years that I hear the Common word 'NDA'... After that 'ubiquitous'... That's more than enough for everyone I presume. They have the best tech, geological the best position, the fastest speed, t
LWLG
shazam1355 shazam1355 51 minutes ago
Jeunke,

Thanks for your quick response. I understand. The reality is that the "silence" is the killer for us all LOL......

It sucks that even though we are working with 3 foundries......1 in Singapore, 1 in USA and 1 in Europe....... but nothing has moved the needle YE
LWLG
Steady_T Steady_T 52 minutes ago
It seems to me that the FDA NDA filing will occur before the EMA renders a decision. My guess is Anavex will wait until the MAA is accepted and past the first stop clock so it will have an understanding of what the regulators want that is not in the original filing. With that knowledge in hand Anav
AVXL
janice shell janice shell 56 minutes ago
LOLOLOL!! Of course not! CMKX was the biggest penny scam of the first decade of the century.

Did you mean to post on this board?
jeunke22 jeunke22 57 minutes ago
It’s 6 million ( as a minimum I assume), not 60 millions. Creating breathing space for the company and a bargain for some old and new investors.
NB
fuagf fuagf 57 minutes ago
Terrible. Is the SEC as crook as it appears to be from an outsider's read of that.
Alexulf Alexulf 1 hour ago
MONDAY - are you prepared and ready? :-)

https://www.barchart.com/stocks/quotes/AITX/overview

This week we will see a sudden RUN.

The AITX website: https://aitx.ai/



GLTA!
AITX
janice shell janice shell 1 hour ago
Keep reading. I found the reference. And really, don't miss this:

https://www.youtube.com/watch?v=YE1f3n_n9UA
Bigfootbud Bigfootbud 1 hour ago
Isaiah 41:10 So do not fear, for I am with you; do not be dismayed, for I am your God.
I will strengthen you and help you; I will uphold you with my righteous right hand.
fuagf fuagf 1 hour ago
shucks
satter satter 1 hour ago
Donald Trump’s Odds Of Election Victory Have Suddenly Gone Into Free Fall



Donald Trump and Kamala Harris are entering the final days of their race for the White House, with Tesla billionaire Elon Musk warning of a "financial emergency."

Trump, who recen
janice shell janice shell 1 hour ago
Absolutely!

Your Recent History

NASDAQ
CYAD
Celyad Oncology
NYSE
NR
Newpark Resources
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved